Article Per Year (5 Year)
p-Index From 2020 - 2025
0.23
P-Index
This Author published in this journals
All Journal International Journal of Integrated Health Sciences
Kartikasari, Andini
Unknown Affiliation
Health Professions

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Eribulin in Heavily Pre-Treated Metastatic Breast Cancer: A Case Series Kartikasari, Andini; Oehadian, Amaylia
International Journal of Integrated Health Sciences Vol 13, No 1 (2025)
Publisher : Faculty of Medicine Universitas Padjadjaran

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.15850/ijihs.v13n1.3908

Abstract

Background: Treatment options are limited for heavily pre-treated metastatic breast cancer patients, with Eribulin showing promise in improving survival outcomes.Objective: To evaluate Eribulin outcomes in patients with MBC. Metastatic or incurable diseases are observed in 4% to 10% of women despite advances in breast cancer treatment. To address this problem, EMBRACE, an important randomized phase III clinical trial was carried out by comparing eribulin to the treatment selected by physicians for individuals with previously treated locally recurrent or metastatic breast cancer (MBC). The results showed a significant and prolonged increase in median overall survival among patients treated with eribulin, compared to those who received the physician's selected treatment.Case Series: This study presents three patients who showed favorable outcomes after treatment with eribulin, despite multiple lines of previous therapy. Patient 1 was diagnosed with triple-negative breast cancer and initially achieved remission before experiencing a recurrence involving a chest lesion and enlarged lymph nodes. After two cycles of eribulin, the patient showed significant improvement. Patient 2 developed brain and liver metastases following the completion of hormonal therapy, prompting the initiation of eribulin as the next line of treatment. Patient 3 had disease progression despite undergoing multiple lines of hormonal and chemotherapy. Eribulin was administered and patient remained stable.Conclusion: Patients with MBC tend to have substantially favorable outcomes with eribulin chemotherapy even after extensive previous treatment.
Co-Authors Amaylia Oehadian